Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Cash & Equivalents (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Cash & Equivalents for 14 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 26.07% to $15.4 million in Q4 2025 year-over-year; TTM through Oct 2025 was $15.4 million, a 26.07% decrease, with the full-year FY2025 number at $15.2 million, down 69.76% from a year prior.
  • Cash & Equivalents was $15.4 million for Q4 2025 at PharmaCyte Biotech, up from $13.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $86.9 million in Q4 2021 to a low of $959270.0 in Q3 2021.
  • A 5-year average of $46.9 million and a median of $55.7 million in 2024 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 8471.89% in 2022, then crashed 73.23% in 2025.
  • PharmaCyte Biotech's Cash & Equivalents stood at $86.9 million in 2021, then dropped by 11.47% to $77.0 million in 2022, then fell by 4.6% to $73.4 million in 2023, then tumbled by 71.62% to $20.8 million in 2024, then fell by 26.07% to $15.4 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Cash & Equivalents are $15.4 million (Q4 2025), $13.2 million (Q3 2025), and $15.2 million (Q2 2025).